IKOULA CLOUD BACKUP, by Acronis : New Flexible and Secure Backup Solution
8.7.2019 11:00:00 EEST | Business Wire | Press release
In the digital age and in the face of the resurgence of cyberattacks, the safeguarding of data becomes an absolute necessity. The scale of attacks spares no business and government, as evidenced the ransomware attack experienced by the city of Baltimore (USA). To help organizations better protecting themselves against the loss or theft of data, IKOULA - Cloud hosting specialist - has developed IKOULA CLOUD BACKUP, by Acronis, a new simple, customizable, flexible and secure, cloud backup solution, in "BaaS" (Backup as a Service) mode.
IKOULA CLOUD BACKUP, by Acronis is an easy-to-use, reliable, automated and scalable cloud backup solution. Easy to deploy, without hardware investment, it can protect all data, applications or files, workstations, mobile devices, and physical or virtual servers.
On the security side, all transferred data are encrypted using an AES-256 encryption algorithm and their access is protected by a unique encryption key without which data recovery is impossible. The solution also includes ransomware protection software. Cloud backup offers a higher level of redundancy and security; Users are thus assured of the total availability of strategic data in the event of a disaster on site or remotely.
Among other assets, usuers have the ability to remotely administer, via a web console, all the physical and virtual terminals of their environment. They can define backups to do, from simple document to full server, automate frequencies and restore all or part from the cloud, at any time and from anywhere.
For more information, visit: https://www.ikoula.com/en/acronis?utm_source=businesswire.com&utm_medium=text&utm_campaign=acronis
To learn how creating your backup easily, please check our video here : https://www.youtube.com/watch?v=4GVMADHw008&vl=zh-Hans
ABOUT IKOULA:
Pioneer of the French Cloud since 1998, IKOULA owns its own Datacenters in France (Reims and Laon), as well as two subsidiaries in Spain and the Netherlands. Because Human Being is part of its DNA, IKOULA maintains a close relationship with its customers, and puts at their disposal reactive teams of experts, available 24/7, able to advise them and accompany them in their activities. IKOULA's teams are multilingual, in order to meet the internationalization challenges of all its customers, spread over more than 60 countries on 4 continents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190708005084/en/
Contact information
IKOULA :
Laurane VASSOR ARCARO – +33 01 84 01 02 69
lvassorarcaro@ikoula.com
Agency :
Céline BERNARD - +33 06.10.78.41.73
Celinebernard_rp@outlook.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
Andersen Global Adds Depth to Tax and Global Mobility Capabilities in Germany30.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its presence through a Collaboration Agreement with Lohr and Company (L+C), a senior-led tax advisory platform, providing practical, responsive solutions in tax compliance, cross-border tax, global mobility, and transfer pricing. Headquartered in Germany with a presence in Austria, L+C advises large multinationals and family-owned companies, family offices, foundations, and high-net-worth individuals. The firm, founded in 2001, specializes in areas such as global mobility, M&A, international tax law, country-by-country reporting, and transfer pricing, including Pillar 2 reporting. Additionally, L+C supports clients with trusts and foundations, tax compliance, payroll and financial accounting, and private financial advisory services. “Collaborating with Andersen Global represents an important step in expanding our international capabilities and strengthening the value we provide to clients navigating increasingly complex cross-border matters,” said Jörg-Andre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom